Risk Factor Analysis for Bevacizumab-induced Severe Hypertension in Advanced Breast Cancer Treatment

Key Result

Pre-existing hypertension is a significant risk factor for bevacizumab-induced severe hypertension in patients undergoing breast cancer treatment.

Key Points

• This research aims to analyze risk factors for severe hypertension induced by bevacizumab in breast cancer treatment.
• Analysis of existing patient data
• Focus on patients with advanced breast cancer
• Assessment of pre-existing hypertension as a risk factor
• Pre-existing hypertension significantly increases the risk of severe hypertension
• Patients with no history of hypertension showed lower rates of severe hypertension when treated with bevacizumab